A Research Guide for
Asthma

It is surprisingly common to be told you have asthma based on symptoms alone and handed an inhaler without ever having your breathing measured — and that shortcut causes real problems in both directions. Some people are labeled asthmatic for years when they actually have something else (acid reflux, a vocal-cord problem, anxiety-related breathlessness, or in older adults COPD), while others with genuine asthma are under-treated because no one confirmed it. Asking for objective lung-function testing is one of the most useful things you can do for your own care.

The main test is spirometry, a simple breathing test in which you blow into a machine before and after an inhaler to see whether your airways open up. There is an important timing wrinkle worth knowing: once you start a steroid inhaler, the test becomes harder to interpret, because the medicine calms the very thing the test is trying to detect. So if you can, it is best to have testing done before starting a daily inhaler — and if you have already started one, don't worry, but mention it, because your clinician may use additional tests (such as tracking how your peak-flow varies over two weeks, or a special challenge test) to sort things out.

This matters because an accurate diagnosis changes everything that follows: it tells you whether an inhaler is the right treatment at all, what type of asthma you have, and how to monitor it. If you are about to start a lifelong treatment, it is entirely reasonable — and good medicine — to ask, “Can we confirm this with a breathing test?”

It helps to have a clear picture of what well-controlled asthma actually looks like, because many people quietly accept a level of symptoms that is treatable. Good control means: you have daytime symptoms no more than a couple of times a week, you are not waking at night because of asthma, you rarely need your reliever (again, no more than about twice a week, not counting pre-exercise use), and asthma does not limit your activities — you can exercise, work, and sleep normally. If you fall short of that, the answer is usually that your treatment can be improved, not that this is “just how your asthma is.”

Two traps keep people from good control. The first is normalizing symptoms: if you have slowly cut back on activities, kept the reliever always within reach, or come to expect a nightly cough, you may not realize how much room there is to feel better — which is why clinicians use short questionnaires (like the Asthma Control Test) to measure control rather than relying on “I'm fine.” The second is judging control by how you feel today rather than your pattern over weeks, including how many attacks and steroid courses you have had — even one or two flares a year needing steroid tablets signals that control isn't where it should be.

The practical move is to treat any of these shortfalls as a reason to revisit your plan with your clinician — check technique and adherence first, then adjust treatment. The goal is not merely to avoid emergencies but to live with asthma in the background, and that goal is realistic for almost everyone.

Spirometry measures how much air you can blow out and how quickly. It is painless, takes about 15 minutes, and is performed in most pulmonology and many primary care offices:

• FEV1 (Forced Expiratory Volume in 1 second): The volume of air you can forcefully exhale in one second. Reduced FEV1 indicates airway obstruction.
• FVC (Forced Vital Capacity): The total volume of air you can exhale after a maximum inhalation.
• FEV1/FVC ratio: The key diagnostic number. A ratio below 0.70 (or below the lower limit of normal for age) indicates airflow obstruction.
• Bronchodilator reversibility: After baseline spirometry, you inhale a bronchodilator (usually albuterol) and repeat the test 15–20 minutes later. An improvement of ≥12% and ≥200 mL in FEV1 confirms reversible airflow obstruction — highly suggestive of asthma.

Normal spirometry does not rule out asthma if it is performed when you are symptom-free. If suspicion remains high, additional testing may be needed.

A peak flow meter is a small, portable device that measures how fast you can blow air out. While less precise than spirometry, it is useful for home monitoring:

• Diagnostic use: PEF variability greater than 10% in adults or 13% in children (measured as the difference between morning and evening readings over 2 weeks, divided by the average) supports an asthma diagnosis.
• Monitoring use: Once your “personal best” PEF is established, daily readings help track control and detect worsening before symptoms become severe. PEF is a core component of Asthma Action Plans.
• How to use: Stand up, take a deep breath, seal your lips around the mouthpiece, and blow out as hard and fast as you can. Record the best of three attempts. Do this each morning before taking medications.

FeNO is a simple breath test that measures nitric oxide in your exhaled breath. Elevated FeNO indicates eosinophilic (allergic) airway inflammation:

• ≥25 ppb in adults (≥20 ppb in children): Suggests eosinophilic airway inflammation and a likely response to inhaled corticosteroids
• <25 ppb: Makes eosinophilic inflammation less likely but does not rule out asthma — non-eosinophilic asthma subtypes exist
• High FeNO (≥50 ppb): Strongly suggests ongoing eosinophilic inflammation, possibly indicating poor adherence to ICS, allergen exposure, or need for therapy escalation

FeNO is most useful for guiding treatment decisions and monitoring inflammation, particularly when deciding whether to start, adjust, or step down inhaled corticosteroids.

When spirometry is normal but asthma is still suspected, provocation (challenge) tests can reveal airway hyperresponsiveness:

• Methacholine challenge: You inhale increasing concentrations of methacholine (a bronchoconstrictor). A 20% drop in FEV1 at a low dose (PC20 ≤ 4 mg/mL) is highly suggestive of asthma. The test has excellent negative predictive value — if negative, asthma is very unlikely.
• Mannitol challenge: Inhaling dry powder mannitol causes airway narrowing through osmotic mechanisms. More specific than methacholine for identifying airway inflammation responsive to ICS. Increasingly used in clinical practice.
• Exercise challenge: Standardized treadmill or cycling exercise protocol used specifically to diagnose exercise-induced bronchoconstriction. A ≥10% fall in FEV1 after exercise confirms EIB.

Challenge testing should be performed in a supervised clinical setting by trained personnel with immediate access to bronchodilators.

Since allergic asthma is the most common type, allergy testing is an important part of the evaluation:

• Skin prick testing: Small amounts of common allergens are applied to the skin (usually the forearm or back) with a tiny prick. A wheal-and-flare reaction within 15–20 minutes indicates sensitization. Fast, inexpensive, and results are available immediately.
• Specific IgE blood tests (formerly RAST): Measures allergen-specific antibodies in the blood. Useful when skin testing is not possible (widespread eczema, antihistamine use, or very young children). Results take a few days.
• Common allergens tested: Dust mites, cat and dog dander, mold (Alternaria, Aspergillus), tree/grass/weed pollens, cockroach allergen

A positive allergy test means you are sensitized — it does not automatically mean the allergen triggers your asthma. Clinical correlation (do symptoms worsen with exposure?) is essential.

Several conditions can mimic asthma. Ruling these out is essential for proper treatment:

• COPD (Chronic Obstructive Pulmonary Disease): Usually in smokers over age 40. Airflow obstruction is persistent and less reversible. Some patients have features of both asthma and COPD (“asthma-COPD overlap”).
• Vocal cord dysfunction (VCD) / Inducible laryngeal obstruction: The vocal cords close paradoxically during breathing, causing stridor and breathlessness that can look exactly like asthma. Does not respond to bronchodilators. Diagnosed by laryngoscopy during symptoms. Treated with speech therapy breathing techniques.
• Gastroesophageal reflux disease (GERD): Acid reflux can trigger coughing, wheezing, and chest tightness that mimic asthma. GERD is also a common asthma trigger. Treating reflux often improves respiratory symptoms.
• Heart failure: Can cause wheezing (“cardiac asthma”), dyspnea, and cough, especially when lying flat. Distinguished by cardiac testing (BNP, echocardiogram).
• Chronic cough from other causes: Upper airway cough syndrome (post-nasal drip), eosinophilic bronchitis (cough without airflow obstruction), or medication-induced cough (ACE inhibitors).
• Anxiety and hyperventilation: Can cause chest tightness, breathlessness, and tingling but does not produce wheezing on examination and spirometry is normal.

Diagnosing asthma in young children is challenging because they cannot reliably perform spirometry. Diagnosis is based on clinical patterns:

• Recurrent wheezing episodes: Three or more episodes of wheezing, especially if occurring outside of colds
• Pattern recognition: Symptoms triggered by exercise, laughter, allergens, or cold air; symptoms that are worse at night; symptom improvement with bronchodilator
• Family history: Parental asthma, eczema, or allergies increase the likelihood
• Asthma Predictive Index (API): A tool that estimates the probability that a wheezing preschooler will develop persistent asthma. Includes major criteria (parental asthma, eczema) and minor criteria (allergic rhinitis, wheezing apart from colds, blood eosinophilia)
• Therapeutic trial: If suspicion is high, a trial of low-dose ICS for 2–3 months can be both diagnostic and therapeutic. Clear improvement supports the diagnosis.

Not every wheezing toddler has asthma. Viral-induced wheezing is very common in young children and often resolves by school age. The distinction matters because treatment differs.

• Have I had spirometry to confirm my asthma diagnosis? If not, can we schedule it?
• What was my FEV1/FVC ratio and bronchodilator response?
• Should I have allergy testing to identify my triggers?
• Would FeNO testing help guide my treatment?
• My spirometry was normal but I still have symptoms — should I have a methacholine challenge?
• Could my symptoms be caused by vocal cord dysfunction, GERD, or another condition?
• My child wheezes frequently — how do you determine if it is asthma at this age?
• How often should I repeat spirometry to monitor my asthma?

If you have had asthma for years, the most important thing to know is that expert advice has fundamentally changed, and the old approach you may have grown up with is now considered unsafe. For decades, people with mild asthma carried a blue “rescue” inhaler (a SABA, such as albuterol/salbutamol) and used a daily “preventer” only if symptoms were frequent. We now know that relying on the rescue inhaler alone is a mistake: it relaxes the airway muscles for quick relief but does nothing about the underlying inflammation that actually drives asthma — and people who lean heavily on a SABA alone have more dangerous attacks, not fewer.

The modern approach fixes this by combining an anti-inflammatory steroid with a fast-acting reliever (formoterol) in a single inhaler, so that every time you reach for relief, you also treat the inflammation. Depending on your severity, you may use this combination inhaler only as needed, or both daily and as needed (an approach called “MART” — maintenance and reliever therapy). The practical upshot: if your doctor switches you from a separate blue rescue inhaler to a single combination inhaler used for both purposes, that is the current standard of care, not an experiment — and you should generally stop using the old SABA-only inhaler once you do.

Two reassurances about the inhaled steroids that worry many people. The doses inhaled for asthma are tiny compared with steroid pills and do not cause the serious side effects people associate with long-term oral steroids; the main local effects (a hoarse voice or oral thrush) are largely prevented by rinsing your mouth after use. And the steroid is what keeps you out of the emergency room — skipping it because you “feel fine” is the most common reason good control quietly slips away. If anything about your inhalers is unclear, ask to have your technique checked: using them incorrectly is extremely common and is the top hidden reason treatment seems not to work.

It sounds almost too simple, but how you use your inhaler may matter as much as which inhaler you have: studies find that most people make at least one technique error, and poor technique is the single most common hidden reason asthma seems “uncontrolled.” The medicine only helps if it reaches your lungs — and a surprising amount is wasted on the back of the throat when the steps are rushed or the timing is off. The most valuable few minutes you can spend is having a nurse, pharmacist, or doctor watch you use your own inhaler and coach you, then confirming you have got it.

Two device-specific points cover most people. With a pressurized (aerosol) inhaler, coordinating the puff with a slow, steady breath in is hard — which is exactly why a spacer (a chamber that holds the puff so you can breathe it in over a few breaths) dramatically improves how much medicine reaches the lungs and is recommended for almost everyone using this type. With a dry-powder inhaler, the opposite applies: you need a quick, forceful breath in to pull the powder deep, and a spacer is not used. Knowing which type you have changes how you should breathe.

Finally, small habits prevent problems: rinse your mouth and spit after using a steroid inhaler to prevent a hoarse voice or oral thrush; keep track of doses so you don't run out or unknowingly use an empty inhaler; and bring all your inhalers to appointments so your technique can be checked on the actual devices you use. If a device feels impossible to use well despite coaching, ask about switching — there is almost always an alternative that fits you better.

Inhaled corticosteroids are the most important class of asthma medication. They work by suppressing the chronic airway inflammation that drives the disease:

• Fluticasone propionate (Flovent, ArmonAir): Widely prescribed, available as MDI and DPI. Low dose: 88–264 mcg/day; medium: 264–440 mcg/day; high: >440 mcg/day.
• Budesonide (Pulmicort): Available as DPI (Turbuhaler) and nebulizer suspension (particularly useful in young children). Favorable safety profile, the most pregnancy data of any ICS.
• Beclomethasone (QVAR): Ultrafine particle formulation that reaches small airways effectively. Available as MDI.
• Mometasone (Asmanex): Once-daily dosing option (DPI). Convenient for adherence.
• Ciclesonide (Alvesco): Prodrug activated in the lungs, resulting in very low oral bioavailability and minimal systemic effects. Once-daily dosing. Often chosen when side effects from other ICS are a concern.

Addressing steroid fears: Inhaled corticosteroids are not the same as the oral or injectable steroids used by athletes. ICS deliver tiny doses directly to the lungs with minimal absorption into the body. Side effects are local (hoarseness, oral thrush) and preventable by rinsing your mouth after each use and using a spacer with MDIs. The growth effect in children is minimal — approximately 0.5 cm in the first year only, with no significant impact on final adult height.

Maintenance And Reliever Therapy (MART), also called SMART (Single Maintenance And Reliever Therapy), is the preferred approach in the 2025/2026 GINA guidelines for most patients. One inhaler serves as both your daily controller and your as-needed reliever:

• How it works: You take 1–2 puffs of ICS-formoterol daily as maintenance. When you have symptoms, you take additional puffs of the same inhaler as needed. Formoterol provides fast relief (onset within 1–3 minutes), while the ICS component treats the inflammation driving the symptoms.
• Available formulations:
  • Budesonide-formoterol (Symbicort) — the most studied MART combination
  • Beclomethasone-formoterol (not yet available in the U.S. but widely used internationally)
• Maximum daily dose: Up to 12 puffs (budesonide-formoterol 200/6) total per day; if consistently using more than 8, your maintenance therapy needs to be stepped up.
• Advantages: Simplifies treatment (one inhaler), automatically increases anti-inflammatory therapy during worsening, reduces severe exacerbations compared to traditional approaches, and no risk of SABA overuse.

Important: MART only works with ICS-formoterol inhalers. Do not use ICS-salmeterol (Advair/Breo) as a reliever — salmeterol has a slow onset and is not suitable for acute symptom relief.

When ICS alone or ICS-formoterol MART does not achieve control, additional controllers can be added:

• Long-acting beta-agonists (LABA): Salmeterol (Serevent) and formoterol (Foradil). Always used in combination with ICS — never alone. LABAs relax airway smooth muscle for 12+ hours. Available in combination inhalers: fluticasone-salmeterol (Advair), budesonide-formoterol (Symbicort), fluticasone-vilanterol (Breo Ellipta, once daily), mometasone-formoterol (Dulera).
• Long-acting muscarinic antagonist (LAMA): Tiotropium (Spiriva Respimat) is approved as add-on therapy for patients ≥6 years whose asthma is not controlled on ICS-LABA. It provides additional bronchodilation through a different mechanism (blocking acetylcholine receptors).
• Leukotriene receptor antagonists (LTRA): Montelukast (Singulair) blocks leukotrienes, inflammatory mediators involved in asthma. Less effective than ICS but can be helpful as add-on therapy, particularly in patients with co-existing allergic rhinitis or exercise-induced symptoms. FDA boxed warning: Montelukast carries a warning about serious neuropsychiatric effects including agitation, depression, suicidal thinking, and sleep disturbances. Discuss risks and benefits with your provider. Monitor for mood or behavior changes, especially in children.

Short-acting beta-agonists like albuterol (ProAir, Ventolin, Proventil) and levalbuterol (Xopenex) relax airway smooth muscle within minutes, providing rapid relief of acute symptoms:

• Onset: 1–5 minutes. Duration: 4–6 hours.
• Still essential for acute settings: SABA remains the mainstay for emergency treatment, nebulizer therapy in young children, and pre-exercise treatment in some patients.
• The shift: GINA no longer recommends SABA as the sole reliever for routine asthma management. Patients using SABA alone are not receiving anti-inflammatory treatment, which increases the risk of severe exacerbations.
• Warning sign: Using your SABA more than 2 times per week (excluding pre-exercise use) indicates uncontrolled asthma and the need for increased controller therapy. Using 3 or more SABA canisters per year is associated with increased risk of severe exacerbation.

Common side effects include tremor, increased heart rate, and jitteriness. These are usually mild and transient.

The best medication in the world is useless if it does not reach your lungs. Choosing the right device and using it correctly is as important as choosing the right drug:

Device types:

• Metered-dose inhaler (MDI): The most common device. Requires coordination between pressing the canister and inhaling. Always use with a spacer/valved holding chamber (except with ultrafine particle formulations like QVAR) to improve lung delivery and reduce oral deposition.
• Dry powder inhaler (DPI): Breath-activated — no coordination needed. Requires a forceful inhalation. Examples: Diskus, Ellipta, Turbuhaler. Not suitable for young children or patients in severe distress.
• Soft mist inhaler (SMI): Respimat device. Produces a slow-moving aerosol mist. Does not require a spacer. Easier to coordinate than MDI.
• Nebulizer: Converts liquid medication to a fine mist for inhalation through a mask or mouthpiece. Treatment takes 5–15 minutes. Used primarily for young children, elderly patients, and during severe exacerbations.

MDI technique (with spacer):

1. Remove the cap and shake the inhaler well
2. Attach the spacer to the inhaler
3. Breathe out fully, away from the spacer
4. Place the spacer mouthpiece in your mouth and seal your lips around it
5. Press the canister once to release a puff
6. Breathe in slowly and deeply for 3–5 seconds
7. Hold your breath for 10 seconds (or as long as comfortable)
8. If a second puff is prescribed, wait 30–60 seconds and repeat
9. Rinse your mouth with water and spit after using ICS

DPI technique:

1. Load the dose according to the device instructions (each DPI is different)
2. Breathe out fully, away from the device (never exhale into the DPI)
3. Place the mouthpiece in your mouth and seal your lips
4. Breathe in quickly and deeply — forcefully enough to move the powder
5. Hold your breath for 10 seconds
6. Rinse your mouth with water and spit after using ICS

Ask your provider or pharmacist to demonstrate and watch your technique at every visit. Video demonstrations are available through the Asthma and Allergy Foundation of America (AAFA) website.

Many patients — and some providers — are hesitant about inhaled corticosteroids due to the word “steroid.” Understanding the facts helps address these concerns:

• Local side effects: Oral thrush (candidiasis) and hoarseness (dysphonia) are the most common. Prevented by using a spacer with MDIs and rinsing the mouth after every use.
• Growth in children: Low-to-medium dose ICS may reduce growth velocity by approximately 0.5 cm in the first year of treatment. Long-term studies show no significant effect on final adult height. Uncontrolled asthma itself impairs growth more than ICS.
• Bone density: High-dose ICS used long-term may have a small effect on bone density. At low-to-medium doses, the risk is negligible. The benefits of asthma control vastly outweigh this concern.
• Adrenal suppression: Extremely rare at standard doses. A concern only with very high-dose ICS used for prolonged periods. Never abruptly stop high-dose ICS without medical guidance.
• Overall risk-benefit: The risks of uncontrolled asthma (hospitalization, ICU admission, airway remodeling, death) are far greater than the minimal risks of ICS at appropriate doses.

Giving asthma medications to children requires patience, consistency, and the right technique:

• Under 4 years: Use an MDI with a spacer and face mask. Ensure a tight seal around the mouth and nose. Count 5–6 breaths through the mask after each puff. Nebulizer is an alternative.
• Ages 4–6: Transition from face mask to mouthpiece on the spacer. Practice with the child before medication is loaded.
• Ages 6+: DPIs become an option if the child can generate sufficient inspiratory flow.
• School medications: Ensure the school has a copy of the Asthma Action Plan, an emergency supply of reliever medication, and permission for the child to carry and self-administer their inhaler.
• Adherence tips: Build medications into daily routines (after brushing teeth), use sticker charts for younger children, and explain to older children why controllers work even when they feel fine.

• Am I on the right type and dose of controller medication for my asthma severity?
• Should I switch to ICS-formoterol MART therapy (one inhaler for both control and relief)?
• Can you watch me use my inhaler and correct my technique?
• Am I using the right type of inhaler device for my age and ability?
• Is a spacer necessary with my current inhaler? Do I have the right one?
• How often am I using my reliever — and is that too often?
• I’m concerned about side effects from inhaled steroids. What are the actual risks at my dose?
• My child is on montelukast — should I be watching for neuropsychiatric side effects?
• When can we consider stepping down my medications?

An asthma action plan only helps if you understand it and keep it somewhere you will actually see it — on the fridge, in your phone, shared with family. The plan works like a traffic light. In the green zone you feel well, breathe normally, and rarely need your reliever; you simply continue your usual medicines. In the yellow zone — a cold settling on your chest, more coughing or wheezing, waking at night, or needing your reliever more than usual — the plan tells you exactly how to step up treatment early, which is the whole point: catching a flare in the yellow zone often prevents a full-blown attack.

The red zone is an emergency: severe breathlessness, a reliever that isn't working or wears off within an hour or two, difficulty speaking in full sentences, or lips or fingernails turning blue. The plan should say plainly to take your emergency medicine and get urgent help or call emergency services — not to wait and see. Knowing these signs in advance, when you are calm and well, is far easier than trying to judge severity in the middle of a frightening attack.

Two things make a plan genuinely useful. First, have your clinician fill it out with you and update it whenever your medicines change, so it always matches what you actually take. Second, learn your own early warning signs — many people have a personal pattern (a particular cough, a throat itch, or a drop in their peak-flow reading) that precedes trouble by a day or two. Acting on those early signals, using the plan, is how you stay in control rather than reacting to crises.

Many asthma deaths are preventable and happen because warning signs were misread or help was sought too late — so knowing, in advance, exactly what counts as an emergency is genuinely lifesaving. Call for emergency help (or go straight to an emergency department) if: your reliever isn't helping or its effect wears off within an hour or two; you are too breathless to speak in full sentences, eat, or sleep; your breathing is fast and hard and you are using neck or chest muscles to breathe; your lips or fingernails look blue or grey; or a young child is unusually drowsy, floppy, or struggling to feed. Do not wait to “see if it settles” — take your emergency treatment and get help at the same time.

While waiting for help, the standard rescue approach is to take repeated doses of your reliever (commonly one puff every 30–60 seconds up to about 10 puffs, ideally through a spacer), sit upright, try to stay calm, and start the emergency steroid if your action plan instructs it. Repeating the reliever while help is on the way is safe and buys time; under-treating out of worry about “too much” inhaler is the more dangerous error in a true attack.

A few things change the rules and warrant extra caution: a history of a previous severe or ICU attack, needing oral steroids in the past year, or using a lot of reliever recently all mark you as higher-risk, and you should have a lower threshold for seeking help. After any emergency visit, see your regular clinician within a week or two even if you feel fine — the period right after an attack is when you are most likely to have another, and it is the best moment to adjust your treatment so the next one doesn't happen.

Asthma Action Plans use a traffic-light color system to guide decision-making based on symptoms and peak flow readings:

GREEN ZONE — Doing Well

• No coughing, wheezing, chest tightness, or shortness of breath
• Can do usual activities and exercise without difficulty
• Sleep through the night without symptoms
• Peak flow: ≥80% of personal best
• Action: Continue daily controller medications as prescribed. This is your goal zone.

YELLOW ZONE — Getting Worse (Caution)

• Coughing, wheezing, chest tightness, or shortness of breath
• Waking at night due to symptoms
• Some limitation of usual activities
• Peak flow: 50–80% of personal best
• Action: Use your reliever inhaler. Increase controller therapy as specified in your plan (e.g., quadruple ICS dose, or increase MART puffs). If using ICS-formoterol MART, take 1–2 additional puffs as needed. If not improving in 2–3 days, or if entering the Yellow Zone frequently, contact your provider.

RED ZONE — Medical Alert (Emergency)

• Severe shortness of breath — difficulty speaking in full sentences
• Reliever inhaler provides no improvement or wears off quickly
• Lips or fingernails turn bluish (cyanosis)
• Peak flow: <50% of personal best
• Action: Use your reliever inhaler immediately (4–8 puffs via spacer, or nebulizer). Start oral corticosteroids if prescribed in your plan. Call 911 or go to the emergency room immediately. Do not wait to see if you improve.

Asthma exacerbations (flare-ups, attacks) rarely come out of nowhere. Learning to recognize early warning signs gives you time to act before the situation becomes dangerous:

• Subtle early signs: Slight cough, especially at night or early morning. Mild chest tightness. Needing your reliever more than usual. Drop in peak flow readings by 10–20%.
• Progressing symptoms: Increased frequency and severity of coughing and wheezing. Exercise intolerance. Waking from sleep. Anxiety or a feeling that something is “off” with breathing.
• In children: Watch for increased coughing at night, avoidance of physical play, irritability, decreased appetite, and dark circles under the eyes (allergic shiners).

Act at the first signs. Yellow Zone actions taken early can prevent a Red Zone emergency. This is why daily peak flow monitoring is valuable — you can detect changes before you feel them.

Go to the emergency room or call 911 immediately if:

• You are struggling to breathe and your reliever inhaler is not helping
• You cannot speak in full sentences due to breathlessness
• Your lips, fingernails, or face turn blue or gray
• Your chest, neck, or rib muscles are pulling in with each breath (retractions)
• Your peak flow is below 50% of your personal best after using your reliever
• You feel panicked about your breathing or sense that something is seriously wrong

While waiting for help: Use your reliever inhaler every 20 minutes (up to 3 treatments). Sit upright. Stay calm. Take oral corticosteroids if they are part of your action plan. Have someone stay with you.

Short courses of oral corticosteroids (OCS) are used for moderate-to-severe exacerbations that do not respond to increased inhaler therapy:

• Adults: Prednisolone or prednisone 40–50 mg/day for 5–7 days. No taper is needed for courses under 14 days.
• Children: Prednisolone 1–2 mg/kg/day (max 40 mg) for 3–5 days.
• Timing: Start early in an exacerbation — do not wait for symptoms to become severe. Early OCS use can prevent hospitalization.
• Side effects of short courses: Increased appetite, mood changes (irritability, insomnia, anxiety), elevated blood sugar, and stomach upset. These resolve after the course is completed.
• Frequent OCS use is a warning sign: Needing more than 2 OCS bursts per year indicates uncontrolled asthma and the need to reassess your treatment plan. Frequent OCS use carries cumulative risks including osteoporosis, diabetes, weight gain, and adrenal suppression. This is a strong indication for biologic therapy evaluation.

• Can we create (or update) my written Asthma Action Plan today?
• What is my personal best peak flow, and how was it determined?
• Exactly what should I do in the Yellow Zone — which medications, what doses?
• Should I have oral corticosteroids at home for emergencies?
• How many times have I needed oral steroids this year — is that too often?
• When should I call your office versus going to the ER?
• Does my child’s school have a copy of the action plan?
• When should we review and update my action plan?

Triggers are the things that set off your airways, and the useful insight is that they are highly personal and often additive — no single exposure may bother you, but several together (a cold, plus pollen, plus a smoky day) can tip you over. The first step is detective work: a simple diary noting when symptoms flare, where you were, and what you were doing often reveals patterns that aren't obvious in the moment. Common culprits include respiratory infections (the number-one trigger for most people), allergens (dust mites, pet dander, mold, pollen, cockroach), tobacco and wood smoke, air pollution, cold dry air, exercise, strong scents, and certain medications.

Some triggers are worth real effort to control at home, because the payoff is large: reducing dust-mite exposure (allergen-proof mattress and pillow covers, hot-washing bedding), fixing damp and mold, keeping pets out of the bedroom, and never allowing smoking indoors. Checking the daily air-quality index and staying indoors with windows closed on high-pollution or wildfire-smoke days is increasingly important. A HEPA air purifier in the bedroom helps many people, while air-quality apps make it easy to plan around bad days.

But a crucial balance deserves emphasis: the goal is to tame triggers, not to let them shrink your life. Exercise is a perfect example — it is a common trigger, but the answer is almost never to stop exercising (which harms your overall health and lung fitness) and almost always to prepare for it: use your reliever or ICS-formoterol beforehand, warm up gradually, and keep your controller treatment optimized. Well-controlled asthma should let you do almost anything; if a trigger you can't avoid is regularly causing symptoms, that is a sign to revisit your medicines with your clinician rather than to give up the activity.

Allergens are the most common triggers in allergic asthma. Reducing exposure requires specific, targeted strategies:

• Dust mites: Microscopic organisms that thrive in warm, humid environments (bedding, upholstered furniture, carpets). Encase mattresses, pillows, and box springs in allergen-proof covers. Wash bedding weekly in hot water (≥130°F / 54°C). Remove carpeting from bedrooms if possible. Keep indoor humidity below 50%.
• Pet dander: Proteins in skin flakes, saliva, and urine from cats, dogs, and other animals. Keeping pets out of bedrooms and off upholstered furniture reduces exposure. HEPA air purifiers in bedrooms help. Washing pets weekly reduces but does not eliminate allergen levels. Note: there is no truly “hypoallergenic” breed.
• Mold: Fix water leaks promptly. Keep bathrooms well ventilated. Clean visible mold with soap and water. Use a dehumidifier in damp basements. Remove moldy materials that cannot be cleaned.
• Pollen: Monitor local pollen counts (pollen.com, weather apps). Keep windows closed during high-pollen days. Shower and change clothes after outdoor activities. Run air conditioning with clean filters.
• Cockroach allergen: A potent asthma trigger, particularly in urban environments. Eliminate food and water sources. Seal cracks and openings. Use bait traps rather than sprays (which can worsen asthma). Professional pest control may be needed.

• Tobacco smoke: The most important irritant trigger. If you smoke, quitting is the single most impactful action you can take for your asthma. Secondhand and thirdhand smoke (residue on surfaces) also trigger symptoms. Vaping/e-cigarettes are not safe alternatives for people with asthma.
• Air pollution: Ozone, particulate matter (PM2.5, PM10), nitrogen dioxide, and sulfur dioxide all worsen asthma. Monitor local air quality (AirNow.gov) and limit outdoor activity on high-pollution days.
• Strong odors and fumes: Perfumes, cleaning products, paint fumes, and cooking odors can trigger bronchoconstriction. Use unscented products when possible. Ensure good ventilation when using chemicals.
• Wood smoke: Fireplaces and wood-burning stoves are significant indoor air pollutant sources. If you have asthma, avoid wood smoke exposure. If you heat with wood, ensure proper ventilation and consider switching to a cleaner heat source.

Utah’s geography and climate create unique asthma challenges:

• Winter inversions: Cold, stagnant air becomes trapped in Utah’s valleys (especially the Salt Lake, Utah, and Cache Valleys), concentrating PM2.5 particulate pollution to unhealthy levels for days or weeks. During inversions, limit outdoor activity, exercise indoors, keep car windows closed, and monitor the Utah Division of Air Quality (air.utah.gov) daily.
• Wildfire smoke: Utah experiences increasing wildfire smoke exposure, particularly July through October. Smoke contains fine particles that penetrate deep into the lungs. During smoke events: stay indoors with windows closed, run HVAC with high-quality filters (MERV 13+) or portable HEPA purifiers, wear an N95 mask if outdoor exposure is unavoidable, and avoid outdoor exercise.
• High altitude and dry air: Much of Utah is above 4,000 feet. Higher altitude means drier and cooler air, which can trigger bronchoconstriction. Hydrate well, use a scarf or buff over your mouth and nose in cold weather, and consider a humidifier indoors during winter.
• Seasonal pollen: Utah has significant tree pollen (February–May), grass pollen (May–July), and weed/ragweed pollen (August–October). Mountain cedar and sagebrush are particularly prevalent.

Exercise-induced bronchoconstriction (EIB) occurs in up to 90% of people with asthma, but it should not prevent physical activity. Exercise is beneficial for cardiovascular health, weight management, and overall asthma control:

• Warm up gradually: A 10–15 minute warm-up can reduce EIB severity by inducing a refractory period
• Pre-treatment: If EIB persists despite good asthma control, take 1–2 puffs of your reliever (SABA or ICS-formoterol) 15 minutes before exercise. This prevents bronchoconstriction in most people.
• Choose your environment: Warm, humid air is less likely to trigger EIB than cold, dry air. Swimming in an indoor heated pool is one of the best activities. During inversions or high-pollen days, exercise indoors.
• Cool down properly: Avoid stopping intense exercise abruptly, which can trigger rebound bronchoconstriction
• Reassuring fact: Many elite athletes have asthma and EIB, including Olympic medalists in swimming, cycling, and track. With proper management, there is no sport that is off-limits.

Respiratory viral infections are the most common trigger for asthma exacerbations, particularly in children:

• Rhinovirus (common cold): The most frequent trigger of asthma exacerbations in both children and adults. Up to 80% of asthma exacerbations in children are triggered by viral infections.
• Influenza and RSV: Can cause severe exacerbations. Annual influenza vaccination is strongly recommended for everyone with asthma.
• COVID-19: People with asthma should stay current on COVID-19 vaccinations. Well-controlled asthma does not appear to increase COVID-19 severity, but uncontrolled asthma may.
• Prevention: Hand hygiene, avoiding close contact with sick individuals, and staying current on vaccinations (flu, COVID, pneumococcal for those indicated) are the best strategies.
• During a cold: Increase monitoring (peak flow, symptoms). Follow your Yellow Zone action plan early. Do not wait for symptoms to worsen before increasing treatment.

• Weather changes: Rapid changes in temperature, humidity, or barometric pressure can trigger symptoms. Cold air is a common trigger — breathe through your nose or cover your mouth with a scarf in cold weather.
• GERD (Gastroesophageal reflux): Up to 75% of people with difficult-to-control asthma have GERD. Acid reflux can trigger bronchoconstriction through vagal nerve stimulation or microaspiration. Treating GERD with proton pump inhibitors can improve asthma symptoms in some patients.
• Medications: Beta-blockers (even eye drops for glaucoma) can trigger severe bronchospasm in people with asthma. NSAIDs/aspirin trigger reactions in 7–15% of adults with asthma (AERD). Always inform every healthcare provider — including dentists and ophthalmologists — that you have asthma.
• Occupational exposures: Over 400 workplace substances can cause or worsen asthma. Common culprits include isocyanates, flour and grain dust, latex, wood dust, and cleaning agents. If symptoms improve on days off, occupational asthma should be investigated.
• Emotional stress and strong emotions: Laughing, crying, or yelling can trigger bronchoconstriction through hyperventilation. Stress does not cause asthma but can worsen an existing condition.

A comprehensive approach to your home environment can significantly reduce allergen and irritant exposure:

• Allergen-proof bedding encasements: Zippered covers for mattresses, pillows, and duvets. Look for covers with a pore size ≤6 microns.
• HEPA air purifiers: Effective at removing airborne particles including pet dander, dust mite allergen fragments, and pollen. Place in the bedroom and main living areas. Replace filters as recommended.
• HVAC filters: Use MERV 11–13 filters and replace every 1–3 months. Have ducts cleaned periodically.
• Humidity control: Maintain indoor humidity at 30–50%. Too high promotes dust mites and mold; too low (common in Utah winters) irritates airways. Use a hygrometer to monitor.
• Flooring: Hard flooring (wood, tile, laminate) harbors fewer allergens than carpet. If carpet removal is not possible, vacuum weekly with a HEPA-filter vacuum.
• Integrated pest management: Address cockroach and rodent allergens through sealing entry points, eliminating food sources, and targeted baits rather than broadcast pesticide sprays.

For patients with allergic asthma, immunotherapy can modify the underlying allergic response:

• Subcutaneous immunotherapy (SCIT / allergy shots): Regular injections of increasing doses of specific allergens over 3–5 years. Reduces asthma symptoms, medication use, and airway hyperresponsiveness. Most effective for dust mite, pollen, and pet dander allergies. Requires in-office administration due to small risk of anaphylaxis.
• Sublingual immunotherapy (SLIT / allergy tablets): Daily tablets dissolved under the tongue at home. FDA-approved options include grass pollen (Grastek), ragweed (Ragwitek), and dust mite (Odactra). Convenient but limited to single-allergen treatment.
• Who benefits most: Patients with confirmed allergic asthma (positive skin testing or specific IgE) where allergen avoidance alone is insufficient and medication burden is significant.

Immunotherapy is the only treatment that can modify the underlying immune response rather than just controlling symptoms. Discuss with an allergist whether it is appropriate for your situation.

• What are my specific asthma triggers based on my history and allergy testing?
• Which environmental control measures would help me most?
• Am I a candidate for allergen immunotherapy (allergy shots or tablets)?
• How should I manage my asthma during Utah’s winter inversions and wildfire season?
• What should I do before exercising to prevent symptoms?
• Could GERD be contributing to my asthma symptoms?
• Are any of my current medications (including eye drops) unsafe for asthma?
• Should I get a HEPA air purifier? What specifications should I look for?

If your asthma stays uncontrolled despite taking your medicines, it is easy to feel that you are failing — but true severe asthma is a distinct biological condition, not a sign that you haven't tried hard enough. That said, before labeling asthma “severe,” a good specialist first checks the things that masquerade as severe disease: whether the inhaler technique is right (incorrect technique is extremely common), whether the medicine is being taken consistently, whether the diagnosis is correct, and whether other problems — nasal allergies, reflux, sleep apnea, obesity — are adding to the burden. Fixing these resolves a surprising amount of “severe” asthma without any new drug.

For genuinely severe asthma, the last decade has transformed what is possible. A class of treatments called biologics — injections given every few weeks or months — target the specific immune pathways that drive the inflammation, and for the right patient they dramatically reduce attacks and can free people from the cycle of repeated steroid pills. Which biologic is right depends on your “phenotype,” identified by simple blood tests (an eosinophil count), a breath test (FeNO), and allergy testing. This is why referral to an asthma specialist matters: matching the biologic to your biology is what makes it work.

One goal deserves special emphasis: getting off long-term steroid pills. Frequent or continuous oral steroids (prednisone) cause serious cumulative harm — bone thinning, diabetes, cataracts, weight gain, and more. If you are relying on steroid pills to breathe, that is itself a reason to seek specialist care, because the modern aim is to control your asthma with targeted treatment and reserve steroid pills for genuine emergencies. Needing frequent prednisone is not a stable place to stay; it is a signal that better options should be explored.

Severe asthma is not one disease. Identifying the specific inflammatory phenotype is essential for selecting the right biologic therapy:

• T2-high (eosinophilic/allergic): The most common severe asthma phenotype (~60–80%). Driven by Type 2 inflammation involving eosinophils, IgE, and cytokines IL-4, IL-5, and IL-13. Biomarkers:
  • Blood eosinophils ≥150 cells/μL (higher counts predict better biologic response)
  • FeNO ≥20 ppb (especially ≥25 ppb)
  • Elevated total IgE (30–1500 IU/mL for omalizumab eligibility)
• T2-low (non-eosinophilic): Less common (~20–40%). May involve neutrophilic inflammation or pauci-granulocytic (few inflammatory cells) patterns. Fewer targeted therapies available, though tezepelumab has shown efficacy. Often associated with obesity, smoking history, or late-onset asthma.

Your severe asthma specialist will order blood eosinophils, FeNO, total IgE, and possibly sputum analysis to determine your phenotype. This guides which biologic is most likely to work for you.

Biologic medications are monoclonal antibodies that target specific molecules in the inflammatory cascade. They have transformed the treatment of severe asthma, dramatically reducing exacerbations, OCS use, and hospitalizations:

• Omalizumab (Xolair): Anti-IgE. The first asthma biologic (approved 2003). Binds to IgE, preventing it from triggering allergic inflammation. For allergic asthma with elevated IgE (30–1500 IU/mL) and sensitization to perennial allergens. Ages ≥6 years. Injection every 2–4 weeks (dose based on weight and IgE level). Well-established safety record.
• Mepolizumab (Nucala): Anti-IL-5. Reduces eosinophil production by blocking IL-5. For eosinophilic asthma (blood eosinophils ≥150 cells/μL). Ages ≥6 years. Subcutaneous injection 100 mg every 4 weeks. Reduces exacerbations by ~50%.
• Benralizumab (Fasenra): Anti-IL-5Rα. Unlike mepolizumab, which blocks the cytokine, benralizumab targets the IL-5 receptor directly, causing rapid and near-complete depletion of eosinophils. For eosinophilic asthma. Ages ≥12 years. Injection every 4 weeks × 3, then every 8 weeks. The less frequent maintenance dosing is an advantage.
• Dupilumab (Dupixent): Anti-IL-4Rα. Blocks both IL-4 and IL-13, two key drivers of T2 inflammation. Broad T2-high eligibility — effective in eosinophilic asthma, IgE-mediated asthma, and patients with elevated FeNO. Ages ≥6 years. Subcutaneous injection every 2 weeks. Also treats co-existing conditions: atopic dermatitis, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
• Tezepelumab (Tezspire): Anti-TSLP (thymic stromal lymphopoietin). The first biologic effective across both T2-high and T2-low asthma because TSLP acts upstream of the T2 pathway. The broadest eligibility of any asthma biologic. Ages ≥12 years. Subcutaneous injection every 4 weeks. Particularly valuable for patients with T2-low disease or those who do not meet criteria for other biologics.
• Reslizumab (Cinqair): Anti-IL-5. For severe eosinophilic asthma (blood eosinophils ≥400 cells/μL in trials). Adults ≥18 years only. Given as an intravenous (IV) infusion every 4 weeks, weight-based (3 mg/kg) — the only asthma biologic that is infused rather than injected, which makes it a more niche option.
• Depemokimab (Exdensur): Anti-IL-5. Approved December 2025. The newest asthma biologic. Its key advantage is dosing: injection only every 6 months (twice yearly), making it the least frequent dosing of any biologic. It is approved as an add-on maintenance treatment for severe eosinophilic asthma (blood eosinophils ~≥300 cells/μL in the past year, or ≥150 at the start of treatment), ages ≥12 years — it does not require having tried another anti-IL-5 first. Approval was based on the SWIFT-1 and SWIFT-2 trials versus placebo (about a 48–58% reduction in exacerbations). (A separate switch study, NIMBLE, did not formally prove it equivalent to switching from monthly mepolizumab, though attack rates stayed low in both groups.)

What to expect: Biologics typically take 4–12 weeks to show benefit. Response is assessed at 4–6 months. The majority of patients on the right biologic see meaningful improvements in exacerbations, symptom control, and OCS reduction. Some patients achieve remission — a state of sustained disease control without exacerbations or OCS use.

Bronchial thermoplasty (BT) is a non-drug procedure for select patients with severe asthma who remain symptomatic despite maximal medical therapy:

• How it works: Controlled radiofrequency energy is delivered to the airway walls during bronchoscopy, reducing the mass of airway smooth muscle. Less smooth muscle means less ability for the airways to constrict.
• Procedure: Performed in 3 sessions, each about 3 weeks apart, treating different lung regions. Each session takes about 1 hour under moderate sedation.
• Evidence: The AIR2 trial showed a significant reduction in severe exacerbations and emergency visits over 5 years post-procedure. Benefits appear durable.
• Limitations: Not widely available. Risk of short-term worsening of asthma symptoms after each treatment session. Patient selection is critical — not suitable for patients with very severe or unstable asthma.

Bronchial thermoplasty is typically considered only after biologic therapy has been tried and found insufficient. Discuss with a severe asthma specialist.

Reducing oral corticosteroid (OCS) use is a major goal of severe asthma management. Chronic OCS use carries serious cumulative risks:

• Osteoporosis and fractures
• Type 2 diabetes and weight gain
• Cataracts and glaucoma
• Adrenal suppression
• Increased infection risk
• Skin thinning and bruising
• Cardiovascular disease

Strategies for reducing OCS dependence:

• Start biologic therapy — all approved biologics have demonstrated OCS-sparing effects
• Optimize inhaled therapy (high-dose ICS-LABA, add LAMA)
• Treat comorbidities aggressively (GERD, rhinosinusitis, obesity)
• Confirm adherence and inhaler technique
• Taper OCS very gradually under specialist supervision — never stop abruptly if you have been on OCS for more than 2–3 weeks, due to the risk of adrenal crisis

An emerging concept in severe asthma management is clinical remission — a sustained state of no symptoms, no exacerbations, normal (or near-normal) lung function, and no need for OCS. Some patients on biologics achieve this state:

• Remission rates vary by biologic and patient population but range from 15–35% in clinical trials
• The definition of remission is evolving but typically includes: no exacerbations, no OCS use, symptom control (ACQ <1.5 or ACT ≥20), and stable or improved lung function
• Whether biologics can be safely discontinued after achieving remission is an active area of research. Currently, most experts recommend continuing biologic therapy, as disease often returns after stopping.

If you have achieved excellent control on a biologic, discuss with your specialist whether a step-down trial might be appropriate for you.

• Is my asthma truly “severe,” or could poor technique, adherence, or a comorbidity be the issue?
• What is my asthma phenotype based on my blood eosinophils, FeNO, and IgE?
• Which biologic therapy is best suited for my specific type of severe asthma?
• How long until I know if the biologic is working?
• Can I stop or reduce my oral corticosteroids once on a biologic?
• What are the side effects and monitoring requirements for my biologic?
• Is bronchial thermoplasty an option for me?
• Am I a candidate for any clinical trials of new severe asthma treatments?
• Should I be seen at a specialized severe asthma center?

Exercise. Well-controlled asthma should not stop you from being active — elite athletes across every sport have asthma. If exercise reliably brings on symptoms, that is usually a sign your day-to-day control needs improving, not a reason to stop. Practical steps help: take your reliever (or as-needed ICS-formoterol) 10–15 minutes before exercise, warm up gradually for 10–15 minutes (this creates a protective “refractory period”), and in cold weather breathe through a scarf or warming mask. Swimming and activities with built-in breaks are often easiest to start with, but with good control almost any activity is open to you.

Pregnancy. This is where the most important and counterintuitive message applies: if you are pregnant, keeping your asthma well controlled is far safer for your baby than easing off your medicines. Uncontrolled asthma reduces the oxygen reaching the baby and raises the risk of complications, whereas the usual inhalers (especially inhaled steroids and relievers) have a long track record of safe use in pregnancy. The single biggest mistake is stopping a controller inhaler out of fear — do not do this; instead, tell your team you are pregnant so they can monitor you more closely (flares are most common in mid-to-late pregnancy) and keep you controlled.

Getting older. Asthma in later life brings its own wrinkles: it can be confused with or coexist with heart disease and COPD, other medications (including some eye drops and blood-pressure drugs called beta-blockers) can worsen it, and arthritis or weaker breath can make some inhalers hard to use. If your inhaler feels awkward or ineffective, ask about a different device or a spacer — getting the medicine into your lungs matters more than which inhaler is “standard.” At every age, the principles are the same: control the inflammation, know your triggers and warning signs, and keep an up-to-date action plan.

Physical activity is not only safe with asthma — it is strongly encouraged. Regular exercise improves cardiovascular fitness, reduces inflammation, and can actually improve asthma control over time:

• Best practices: Warm up for 10–15 minutes. Use pre-exercise treatment if prescribed. Stay hydrated. Choose indoor exercise during inversions, high pollen, or wildfire smoke days. Cool down gradually.
• Best activities: Swimming (warm, humid air is well-tolerated), walking, cycling, yoga, and team sports with intermittent activity. Activities in cold, dry air (cross-country skiing, ice skating) may require more careful preparation.
• For children: Children with asthma should participate fully in physical education and sports. Provide the school with an action plan and pre-exercise medication instructions. Do not let asthma become an excuse for inactivity — fit children with asthma have better long-term outcomes.

Asthma affects 4–8% of pregnancies. Proper management is critical because uncontrolled asthma poses greater risks to mother and baby than asthma medications do:

• The rule of thirds: During pregnancy, asthma improves in about one-third of women, worsens in one-third, and remains stable in one-third. Exacerbations are most common in the second trimester.
• Risks of uncontrolled asthma in pregnancy: Preeclampsia, preterm birth, low birth weight, and increased risk of cesarean delivery. These risks are reduced with proper asthma control.
• Medications in pregnancy: Budesonide is the preferred ICS (most safety data). Albuterol is considered safe for relief. Most controller medications can be continued — the risk of stopping treatment and having an exacerbation is greater than the risk of continuing medications.
• Key principle: It is safer for a pregnant woman with asthma to be treated with asthma medications than to have uncontrolled symptoms and exacerbations. Never stop asthma medications during pregnancy without discussing with your provider.
• Breastfeeding: Inhaled asthma medications are considered compatible with breastfeeding. Continue your usual treatment.

School management is a critical component of pediatric asthma care:

• School Asthma Management Plan: Provide the school nurse and teacher with a copy of your child’s Asthma Action Plan, a list of triggers, and emergency contact information. Update annually.
• Inhaler access: All 50 states have laws allowing students to carry and self-administer asthma inhalers at school. Ensure your child has permission to carry their reliever. Keep a backup inhaler with the school nurse.
• Classroom accommodations: Seat away from windows (pollen), away from classroom pets, and near the door for easy access to the nurse. Allow breaks if symptomatic. Modified PE participation during poor air quality days.
• Field trips and activities: Ensure medications travel with the child. Brief chaperones on the action plan. Identify the nearest emergency facility.
• Communication: Establish a regular communication channel with the school nurse. Report changes in medications or health status promptly.

• Carry medications in your hand luggage — never in checked bags. Bring more than you think you will need.
• Carry a copy of your Asthma Action Plan and a letter from your doctor listing your diagnoses and medications (especially important for international travel with controlled substances).
• Research your destination: Air quality, altitude, allergen seasons, and availability of medical care. Know the local emergency number.
• Air travel: Cabin air is dry and recirculated. Stay hydrated. Use a saline nasal spray. Have your reliever accessible (not in the overhead bin). Airplane cabin pressure is equivalent to ~6,000–8,000 feet altitude.
• Travel insurance: Consider travel insurance that covers asthma-related medical care, especially for international trips.
• Accommodations: Request non-smoking, pet-free hotel rooms. If severe allergies, bring your own allergen-proof pillowcase.

The relationship between asthma and mental health is bidirectional and clinically significant:

• Anxiety: People with asthma are 2–3 times more likely to have anxiety disorders. The experience of breathlessness can trigger panic, and panic symptoms can mimic asthma — leading to overuse of rescue inhalers. Learning to distinguish between asthma and anxiety-related breathlessness is important.
• Depression: Occurs at twice the rate in people with asthma compared to the general population. Associated with poorer adherence, worse outcomes, and more exacerbations.
• Children and adolescents: Asthma limitations, school absences, and feeling “different” can affect self-esteem and social development. Watch for signs of social withdrawal, school avoidance, or mood changes.
• What to do: Screen for anxiety and depression at asthma visits. Cognitive behavioral therapy is effective for both asthma-related anxiety and comorbid depression. Treating mental health conditions improves asthma outcomes.

Nocturnal asthma — symptoms that worsen during the night or early morning — affects up to 75% of asthma patients and is a marker of inadequate control:

• Why nighttime? Circadian changes in airway caliber, increased allergen exposure (dust mites in bedding), GERD in supine position, and decreased cortisol levels all contribute.
• Management: Optimize controller therapy (nocturnal symptoms usually respond to ICS dose increase). Allergen-proof bedding. Treat GERD. Elevate the head of the bed if reflux is a factor. Avoid eating 2–3 hours before bed.
• When to escalate: Waking from sleep due to asthma even once per week indicates uncontrolled asthma and warrants treatment adjustment. Frequent nighttime symptoms suggest the need for specialist evaluation.

Two modifiable factors have an outsized impact on asthma control:

Smoking:

• Smoking accelerates lung function decline, reduces ICS effectiveness, and increases exacerbation risk. Quitting is the single most impactful lifestyle change a smoking asthmatic can make.
• Resources: Utah Tobacco Quit Line (1-800-QUIT-NOW), smokefree.gov, nicotine replacement therapy, varenicline, or bupropion — all compatible with asthma medications.
• E-cigarettes/vaping are not safe alternatives for people with asthma. Vaping aerosols contain irritants that can worsen airway inflammation.

Weight management:

• Obesity worsens asthma through mechanical effects (reduced lung volumes), systemic inflammation, and altered immune responses. Obese patients respond less well to ICS.
• Weight loss of even 5–10% of body weight has been shown to significantly improve asthma control, reduce medication needs, and improve quality of life.
• Bariatric surgery in patients with severe obesity and asthma has been associated with dramatic improvements in asthma outcomes.

• Asthma Control Test (ACT): A 5-question validated questionnaire that scores your control from 5 (poor) to 25 (complete control). A score of 20+ indicates well-controlled asthma. Free and available online. Take it before every provider visit.
• Peak flow diary: Daily morning PEF readings tracked over time reveal trends that may not be apparent from symptoms alone. Especially valuable during high-risk periods (allergy season, inversions, respiratory illnesses).
• Symptom tracking: Keep a brief log of nighttime awakenings, reliever use, activity limitations, and trigger exposures. Apps like AsthmaMD and MyAsthma can simplify this.
• Smart inhalers: Digital devices that attach to or replace standard inhalers and track medication use, time, location, and technique. Some sync with smartphone apps and share data with providers. Examples include Propeller Health sensors and Teva’s Digihaler.
• Regular follow-up: See your provider every 1–3 months when adjusting treatment, and every 3–12 months once stable. Spirometry should be performed annually and after any change in therapy.

• Learn to recognize worsening signs — especially in young children who cannot describe their symptoms. Increased coughing, rapid breathing, chest retractions, and decreased activity are red flags.
• Keep the home environment clean — follow allergen reduction measures consistently. This benefits the whole family.
• Do not smoke anywhere near the person with asthma — not in the car, not in another room, not outside and then coming inside. Thirdhand smoke residue on clothing and furniture is also a trigger.
• Know the action plan — every caregiver (parents, grandparents, babysitters, teachers) should know the Green/Yellow/Red zone plan and where medications are kept.
• Encourage normal activity — children with asthma should play, run, and participate in sports. Overprotection can be as harmful as neglect, leading to deconditioning and social isolation.
• Model adherence — help children take their daily controller medication consistently, even when they feel fine. Make it part of the routine, like brushing teeth.

• Is my asthma well controlled enough for me to exercise safely? What precautions should I take?
• I’m planning a pregnancy — what changes should I make to my asthma treatment?
• My child wakes at night with coughing — is that a sign their asthma is uncontrolled?
• I’m planning a trip — what should I prepare for my asthma?
• I’m feeling anxious about my asthma — could that be affecting my symptoms?
• Would a smart inhaler help me manage my asthma better?
• How much would losing weight help my asthma?
• What is my ACT score, and what does it mean?
• How often do I need follow-up visits and spirometry?

One of the most common questions is whether asthma is permanent. The honest answer is nuanced and genuinely encouraging. Asthma is a chronic condition that, for most people, does not simply disappear — but it is highly controllable, and its severity often changes over a lifetime. Many children with asthma have far milder symptoms or long symptom-free stretches as adults; conversely, some people develop asthma for the first time in adulthood. The realistic goal is not “cure” but control so complete that asthma rarely intrudes on your life — no limits on activity, sleeping through the night, infrequent reliever use, and few or no attacks. That goal is achievable for the large majority of people.

Because severity drifts over time, your treatment is meant to change with it. After a stretch of good control (usually at least three months), your clinician may “step down” to the lowest dose that keeps you well — an important way to avoid over-treatment — though the inhaled steroid is generally not stopped entirely, because the underlying tendency remains. Equally, a season or a life change may call for stepping back up. This is normal and good care, not a sign of failure; asthma management is a dial you and your clinician adjust, not a fixed prescription.

For the small group with severe asthma, even here the outlook has improved dramatically: biologic treatments can bring some patients to a state of “clinical remission” — no attacks, no oral steroids, normal or near-normal breathing. Wherever you fall on the spectrum, the through-line is the same: asthma is something you manage and largely master, not something that has to define how you live.

The cost of asthma medicines — especially newer combination inhalers and biologics — is a real barrier, and the dangerous response is the common one: quietly rationing or skipping the controller inhaler to save money, which leads straight to attacks and emergency visits that cost far more. If cost is a problem, treat it as a medical issue to solve with your team rather than alone, because there are usually options.

Several levers can lower costs without compromising control. Ask your clinician or pharmacist whether a generic, or a different but equivalent inhaler on your plan's formulary, would work — inhaler pricing varies widely between near-identical products. Manufacturer copay cards and patient-assistance programs cover many brand-name inhalers and most biologics for eligible patients. Pharmacy discount programs and comparing prices between pharmacies can help if you are paying cash. And keeping your asthma well controlled is itself cost-saving: it reduces the reliever inhalers, urgent visits, and steroid courses that add up.

What not to do: don't stretch a controller inhaler by skipping doses, don't substitute extra reliever for a controller you can't afford (this is both ineffective and risky), and don't simply stop a biologic without telling your specialist. If you are struggling to afford care, say so plainly at your appointment — social workers, patient navigators, and assistance programs exist precisely for this, and a clinician who knows about the barrier can often find a workable, safe alternative.

• University of Utah — Division of Allergy/Immunology and Pulmonary Medicine: Comprehensive asthma evaluation and management, severe asthma clinic, biologic therapy administration, and clinical trials. Phone: 801-581-2955.
• Intermountain Health — Asthma and Allergy Services: Multiple locations along the Wasatch Front offering asthma management, allergy testing, and immunotherapy. Intermountain Primary Children’s Hospital provides specialized pediatric asthma care. Phone: 801-662-1000.
• Utah Asthma Program (Utah Department of Health): State-funded program providing education, resources, and surveillance data on asthma in Utah. Offers community health worker programs and school-based asthma management support. Website: health.utah.gov/asthma.
• Utah Division of Air Quality (DAQ): Real-time air quality monitoring for all Utah counties. Sign up for air quality alerts. Website: air.utah.gov. Essential during inversions and wildfire season.
• AirNow.gov — Utah: Federal air quality index (AQI) with forecasts. Use the AirNow app for real-time notifications.
• Utah County Health Departments: Many offer asthma education programs, home environmental assessments, and community health resources.

• Asthma and Allergy Foundation of America (AAFA): aafa.org — The leading patient advocacy organization for asthma and allergies. Offers educational programs, support groups, an asthma capital rankings report, and free resources including inhaler technique videos. Helpline: 1-800-7-ASTHMA (1-800-727-8462).
• American Lung Association (ALA): lung.org — Provides the Asthma Basics and Breathe Well, Live Well programs. Offers a lung health helpline (1-800-586-4872), asthma clinical trial information, and air quality advocacy.
• CDC — Asthma Program: cdc.gov/asthma — National surveillance data, guidelines for schools and healthcare providers, and patient education materials.
• NIH / NHLBI (National Heart, Lung, and Blood Institute): nhlbi.nih.gov — Publisher of the Expert Panel Report (EPR-4) asthma management guidelines. Offers free Asthma Action Plan templates and educational brochures.
• Allergy & Asthma Network: allergyasthmanetwork.org — Patient education, advocacy, and a magazine (Allergy & Asthma Today).
• Global Initiative for Asthma (GINA): ginasthma.org — Publishes the annual GINA Report, the most widely used international asthma management guideline. Free to download.

• Propeller Health: FDA-cleared sensor that attaches to standard inhalers. Tracks medication use, sends reminders, records date/time/location of use, and shares data with providers. Detects patterns and identifies environmental triggers. Some insurance plans cover the cost.
• Teva DigiHaler: Built-in sensors in fluticasone (ArmonAir) and albuterol (ProAir) inhalers. Measures inspiratory flow and inhalation duration to provide inhaler technique feedback via a companion app.
• AsthmaMD: Free app for tracking symptoms, triggers, PEF readings, and medications. Generates reports for provider visits.
• AirNow app: Real-time AQI monitoring with customizable health notifications based on your location.
• MyAsthma: Self-management app with action plan integration, symptom tracking, and medication reminders.
• Asthma.com (GSK): Comprehensive patient education website with inhaler technique videos, an ACT assessment tool, and provider discussion guides.

• AAFA Community: Online forum and support community hosted by the Asthma and Allergy Foundation of America. Moderated by trained staff. Offers peer support and Q&A.
• American Lung Association — Better Breathers Clubs: In-person support groups in communities across the country for people with chronic lung conditions including asthma.
• Inspire — Asthma Community: inspire.com — Online health community with moderated discussion forums for asthma patients and caregivers.
• Facebook Groups: Multiple active groups (Asthma Support Group, Severe Asthma Warriors). Peer-moderated; helpful for shared experiences but not a substitute for medical advice.
• Reddit: r/Asthma is an active community for patient discussions, questions, and shared experiences.

• 911: For any life-threatening asthma emergency
• Poison Control: 1-800-222-1222 (accidental medication ingestion or overdose)
• AAFA Helpline: 1-800-727-8462 (asthma and allergy information and referrals)
• American Lung Association Helpline: 1-800-586-4872
• 988 Suicide & Crisis Lifeline: Call or text 988 (for anyone in emotional distress — asthma and mental health are connected)

• Can you recommend an allergist or pulmonologist in the area who specializes in asthma?
• Would a smart inhaler help me track my asthma better?
• Are there asthma education programs or support groups you recommend?
• Am I eligible for any clinical trials for new asthma treatments?
• Can you help me get a home environmental assessment for allergen and trigger reduction?
• What apps or digital tools do you recommend for asthma monitoring?
• How do I find out about air quality alerts in my area?
• If I need emergency care while traveling, what should I have with me?

• University of Utah — Division of Allergy/Immunology — Comprehensive severe asthma clinic, biologic therapy, clinical trials. 801-581-2955.
• University of Utah — Division of Pulmonary Medicine — Difficult-to-control asthma, occupational asthma evaluation. 801-581-2955.
• Intermountain Health — Allergy & Asthma Services — Multiple Wasatch Front locations. Primary Children’s Hospital for pediatric severe asthma. 801-662-1000.
• Utah Asthma Program — State-funded community health workers and school-based programs. health.utah.gov/asthma.

• National Jewish Health — Denver, CO. The nation’s leading respiratory hospital; severe and difficult-to-treat asthma program, biologic center. 800-222-5864.
• Mayo Clinic — Division of Allergic Diseases — Rochester, MN. Comprehensive asthma evaluation. 507-284-2511.
• Brigham and Women’s Hospital — Severe Asthma Program — Boston, MA. 617-732-5500.
• Cleveland Clinic — Respiratory Institute — Cleveland, OH. 216-444-6503.
• UCSF Asthma Clinical Research Center — San Francisco, CA. Active trial site. 415-476-0735.

• VA Salt Lake City Health Care System — pulmonary and allergy services. 801-582-1565.
• VA facilities provide all FDA-approved asthma medications including biologics through the VA formulary.
• Veterans with service-connected respiratory conditions (e.g., burn pit exposure, deployment-related asthma) should file a disability claim with the VA.

• Asthma Canada — asthma.ca. National organization providing education, advocacy, and certified asthma educator directory.
• Canadian Thoracic Society (CTS) — publishes Canadian asthma management guidelines and maintains a specialist directory.
• All GINA Step 5 biologics (omalizumab, mepolizumab, benralizumab, dupilumab, tezepelumab) are approved by Health Canada; provincial formulary coverage varies.

• Royal Brompton & Harefield Hospital — London, UK. One of Europe’s largest severe asthma centers. Part of Guy’s and St Thomas’ NHS Foundation Trust.
• Woolcock Institute of Medical Research — Sydney, Australia. Leading asthma research center (SMART/MART evidence base).
• Global Initiative for Asthma (GINA) — ginasthma.org. International guideline body; annual strategy report is the global standard.

• FeNO (Fractional Exhaled Nitric Oxide) — a breath test measuring airway inflammation. Levels >25 ppb in adults suggest eosinophilic/Type 2 inflammation and predict good ICS response.
• Eosinophils — a type of white blood cell. Elevated blood eosinophils (≥150–300 cells/µL) indicate Type 2 inflammation and may indicate eligibility for biologic therapy.
• ICS (Inhaled Corticosteroid) — the cornerstone controller medication for asthma (e.g., fluticasone, budesonide, beclomethasone). Reduces airway inflammation.
• MART / SMART — Maintenance And Reliever Therapy / Single Maintenance And Reliever Therapy. Using a single ICS-formoterol inhaler as both daily controller and as-needed reliever. Now GINA’s preferred approach across most steps.
• SABA — Short-Acting Beta-Agonist (e.g., albuterol/salbutamol). Rapid bronchodilator for acute relief. No longer recommended as sole treatment.
• LABA — Long-Acting Beta-Agonist (e.g., formoterol, salmeterol). Must always be combined with ICS.
• AERD / Samter’s Triad — Aspirin-Exacerbated Respiratory Disease. A clinical triad of asthma, nasal polyps, and respiratory reactions to aspirin/NSAIDs.
• Airway remodeling — structural changes in the airway walls (thickening, fibrosis) from chronic uncontrolled inflammation. Partially irreversible; a key reason to treat inflammation early.
• Biologic therapy — targeted antibodies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, depemokimab) for severe uncontrolled asthma. Selected based on phenotype and biomarkers.
• PEF (Peak Expiratory Flow) — a simple measure of how fast you can blow air out. Used in asthma action plans to monitor control. Personal best PEF is the reference.